ERBB2 and breast carcinoma: In another illustration of treatment personalization strategy, Humbert et al. showed that ΔSUVmax of the primary tumor after only one cycle of docetaxel plus trastuzumab regimen was able to predict response in patients with HER2 + locally advanced breast cancer, with possibility to improve response by adding pertuzumab26.